CMRX Chimerix Inc

Price (delayed)

$1.15

Market cap

$102.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$76.23M

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious ...

Highlights
The debt has contracted by 37% YoY and by 11% from the previous quarter
The net income has plunged by 148% YoY but it has increased by 3.3% from the previous quarter
The EPS has plunged by 147% YoY but it has grown by 3.1% from the previous quarter
Chimerix's revenue has plunged by 99% YoY and by 71% from the previous quarter
The company's gross profit has shrunk by 99% YoY and by 71% QoQ

Key stats

What are the main financial stats of CMRX
Market
Shares outstanding
89.21M
Market cap
$102.59M
Enterprise value
$76.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
314.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
235.29
Earnings
Revenue
$324,000
EBIT
-$82.1M
EBITDA
-$82.09M
Free cash flow
-$69.17M
Per share
EPS
-$0.93
Free cash flow per share
-$0.78
Book value per share
$2.17
Revenue per share
$0
TBVPS
$2.4
Balance sheet
Total assets
$212.77M
Total liabilities
$19.75M
Debt
$1.3M
Equity
$193.03M
Working capital
$170.67M
Liquidity
Debt to equity
0.01
Current ratio
10.25
Quick ratio
9.91
Net debt/EBITDA
0.32
Margins
EBITDA margin
-25,337.7%
Gross margin
100%
Net margin
-25,338%
Operating margin
-28,723.8%
Efficiency
Return on assets
-35%
Return on equity
-37.9%
Return on invested capital
-41%
Return on capital employed
-42.2%
Return on sales
-25,338%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CMRX stock price

How has the Chimerix stock price performed over time
Intraday
-7.26%
1 week
-2.54%
1 month
25.94%
1 year
-27.22%
YTD
19.48%
QTD
19.48%

Financial performance

How have Chimerix's revenue and profit performed over time
Revenue
$324,000
Gross profit
$324,000
Operating income
-$93.07M
Net income
-$82.1M
Gross margin
100%
Net margin
-25,338%
The net income has plunged by 148% YoY but it has increased by 3.3% from the previous quarter
Chimerix's revenue has plunged by 99% YoY and by 71% from the previous quarter
The company's gross profit has shrunk by 99% YoY and by 71% QoQ
The operating income has shrunk by 54% YoY but it has increased by 3.1% QoQ

Growth

What is Chimerix's growth rate over time

Valuation

What is Chimerix stock price valuation
P/E
N/A
P/B
0.53
P/S
314.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
235.29
The EPS has plunged by 147% YoY but it has grown by 3.1% from the previous quarter
The stock's price to book (P/B) is 81% less than its 5-year quarterly average of 2.8 but 33% more than its last 4 quarters average of 0.4
The equity has declined by 25% year-on-year and by 7% since the previous quarter
CMRX's P/S is 178% higher than its 5-year quarterly average of 113.1
Chimerix's revenue has plunged by 99% YoY and by 71% from the previous quarter

Efficiency

How efficient is Chimerix business performance
CMRX's return on assets has dropped by 135% year-on-year and by 3.6% since the previous quarter
Chimerix's return on equity has shrunk by 133% YoY and by 3.8% QoQ
Chimerix's ROIC has plunged by 116% YoY and by 4.6% from the previous quarter

Dividends

What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMRX.

Financial health

How did Chimerix financials performed over time
The total assets has contracted by 24% YoY and by 6% from the previous quarter
CMRX's quick ratio is down by 21% since the previous quarter and by 7% year-on-year
The debt is 99% less than the equity
The debt has contracted by 37% YoY and by 11% from the previous quarter
The equity has declined by 25% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.